NCT00558363 - ARTS - AVODART After Radical Therapy For Prostate Cancer Study | Biotech Hunter

Enrollment

294

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

March 31, 2011

Conditions

Neoplasms, ProstateProstate Cancer After a Radical Treatment

Interventions

DRUG

Avodart

0.5 mg administered orally once daily

OTHER

placebo

Patients will be randomized at Visit 2 in 1:1 ratio to receive either 0.5 mg dutasteride or placebo

Trial Locations (66)

1162

GSK Investigational Site, Tallinn

8907

GSK Investigational Site, Barcelona

10249

GSK Investigational Site, Berlin

12627

GSK Investigational Site, Berlin

13187

GSK Investigational Site, Berlin

13419

GSK Investigational Site, Tallinn

16303

GSK Investigational Site, Schwedt

16515

GSK Investigational Site, Oranienburg

18014

GSK Investigational Site, Granada

19002

GSK Investigational Site, Guadalajara

19230

GSK Investigational Site, Hagenow

20850

GSK Investigational Site, Mendaro, Guipuzcoa

23970

GSK Investigational Site, Wismar

24143

GSK Investigational Site, Kiel

26789

GSK Investigational Site, Leer

28046

GSK Investigational Site, Madrid

28905

GSK Investigational Site, Getafe

29600

GSK Investigational Site, Marbella

30008

GSK Investigational Site, Murcia

31008

GSK Investigational Site, Pamplona

33521

GSK Investigational Site, Tampere

35039

GSK Investigational Site, Marburg

41013

GSK Investigational Site, Seville

41930

GSK Investigational Site, Bormujo (sevilla)

45100

GSK Investigational Site, Orléans

45200

GSK Investigational Site, Kouvola

46010

GSK Investigational Site, Valencia

47012

GSK Investigational Site, Valladolid

49933

GSK Investigational Site, Angers

63500

GSK Investigational Site, Seligenstadt

69437

GSK Investigational Site, Lyon

73011

GSK Investigational Site, Chambéry

86551

GSK Investigational Site, Aichach

90100

GSK Investigational Site, Oulu

94000

GSK Investigational Site, Créteil

98693

GSK Investigational Site, Ilmenau

115478

GSK Investigational Site, Moscow

128128

GSK Investigational Site, Moscow

04109

GSK Investigational Site, Leipzig

06844

GSK Investigational Site, Dessau

06295

GSK Investigational Site, Eisleben Lutherstadt

06333

GSK Investigational Site, Hettstedt

1091 AC

GSK Investigational Site, Amsterdam

7555 DL

GSK Investigational Site, Hengelo

6229 HX

GSK Investigational Site, Maastricht

6525 GA

GSK Investigational Site, Nijmegen

3015 CE

GSK Investigational Site, Rotterdam

5022 GC

GSK Investigational Site, Tilburg

7101 BN

GSK Investigational Site, Winterswijk

117 837

GSK Investigational Site, Moscow

119 881

GSK Investigational Site, Moscow

01004

GSK Investigational Site, Alava

Unknown

GSK Investigational Site, Alcala de Henares (madrid)

08036

GSK Investigational Site, Barcelona

SE-412 55

GSK Investigational Site, Gothenburg

SE-413 46

GSK Investigational Site, Gothenburg

SE-205 02

GSK Investigational Site, Malmo

SE-701 85

GSK Investigational Site, Örebro

SE-901 85

GSK Investigational Site, Umeå

SE-751 85

GSK Investigational Site, Uppsala

EX2 5DW

GSK Investigational Site, Exeter

SG2 4AB

GSK Investigational Site, Stevenage

NG5 1PB

GSK Investigational Site, Nottingham

BA1 1BX

GSK Investigational Site, Bath

BS2 8HW

GSK Investigational Site, Bristol

NE7 7PN

GSK Investigational Site, High Heaton, Newcastle Upon Tyne